Your browser doesn't support javascript.
Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis.
Crit Rev Oncol Hematol ; 94(3): 261-9, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25797826
ABSTRACT

BACKGROUND:

Chronic lymphocytic leukemia (CLL) is a disease of the lymphoid system, in which the most common therapy is fludarabine plus cyclophosphamide (FC). The addition of rituximab to FC has been used, a combination known as FCR.

OBJECTIVES:

To perform a systematic review with meta-analysis of clinical trials between 2000 and 2012 comparing FC and FCR in patients with CLL.

MATERIAL AND METHODS:

Electronic databases were searched using keywords related to the objectives of this review. The outcomes examined were progression-free survival and complete remission.

RESULTS:

The progression-free survival and the overall survival showed significant difference between the two regimens, with complete remission being more frequent in FCR-treated patients (odds ratio=2.58; 95% CI: 2.13-3.13). Patients treated with FCR showed significantly higher neutropenia and serious adverse reactions.

CONCLUSION:

Despite the favorable results of the FCR regimen on outcomes including complete remission, progression-free survival, and overall survival, there is a lack of methodological rigor and appropriate analyses in many of these studies, and thus, there is a need for further studies examining the effect of rituximab in CLL patients.
Assuntos

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudo: Revisão sistemática Aspecto clínico: Terapia Limite: Humanos Idioma: Inglês Revista: Crit Rev Oncol Hematol Assunto da revista: Hematologia / Neoplasias Ano de publicação: 2015 Tipo de documento: Artigo